EASL Congress webpage publishes survodutide fatty liver data ahead of schedule by accident

The detailed results were not due to be published until Friday.
Photo: Boehringer Ingelheim / PR
Photo: Boehringer Ingelheim / PR
by MARKETWIRE ‎

An abstract of data from a Phase II study of survodutide in fatty liver disease, or MASH, was inadvertently and briefly published on the European Association of the Study of the Liver Congress (EASL) website.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading